Cargando…
Reticulocalbin 3 Is a Novel Mediator of Glioblastoma Progression
SIMPLE SUMMARY: Glioblastoma is the deadliest primary brain tumor. Current treatment strategies for glioblastoma are not effective, and patients exhibit poor survival rates. Emerging studies implicated glioma stem cells (GSCs) in tumor initiation, progression, and therapy resistance. There is an unm...
Autores principales: | He, Yi, Alejo, Salvador, Johnson, Jessica D., Jayamohan, Sridharan, Sareddy, Gangadhara R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093618/ https://www.ncbi.nlm.nih.gov/pubmed/37046668 http://dx.doi.org/10.3390/cancers15072008 |
Ejemplares similares
-
301 Inhibition of lysine-specific histone demethylase 1A (KDM1A/LSD1) attenuates DNA double strand break repair and enhances efficacy of temozolomide in glioblastoma
por: Alejo, Salvador, et al.
Publicado: (2023) -
Reticulocalbin-1 Facilitates Microglial Phagocytosis
por: Ding, Ying, et al.
Publicado: (2015) -
Differential Proteomics Identifies Reticulocalbin-3 as a Novel Negative Mediator of Collagen Production in Human Cardiac Fibroblasts
por: Martínez-Martínez, Ernesto, et al.
Publicado: (2017) -
Reticulocalbin 2 as a Potential Biomarker and Therapeutic Target for Atherosclerosis
por: Li, Jing, et al.
Publicado: (2022) -
Reticulocalbin 3 is involved in postnatal tendon development by regulating collagen fibrillogenesis and cellular maturation
por: Park, Na Rae, et al.
Publicado: (2021)